Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) PT at $22.14

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) has received a consensus recommendation of "Buy" from the nine brokerages that are presently covering the company, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $22.14.

Several analysts recently commented on the stock. Royal Bank of Canada reissued an "outperform" rating and set a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, August 13th. HC Wainwright reiterated a "buy" rating and set a $21.00 price objective on shares of Lexeo Therapeutics in a research report on Thursday. Finally, Chardan Capital reissued a "buy" rating and set a $23.00 price objective on shares of Lexeo Therapeutics in a research note on Friday, October 25th.

Lexeo Therapeutics Price Performance

Shares of LXEO stock traded up $0.03 during mid-day trading on Friday, hitting $7.93. 221,351 shares of the stock traded hands, compared to its average volume of 346,747. Lexeo Therapeutics has a twelve month low of $7.54 and a twelve month high of $22.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.38 and a current ratio of 9.38. The company's 50-day simple moving average is $9.71 and its 200-day simple moving average is $12.54. The firm has a market cap of $262.17 million and a price-to-earnings ratio of -0.54.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.64). As a group, equities research analysts expect that Lexeo Therapeutics will post -2.76 earnings per share for the current year.

Insider Buying and Selling at Lexeo Therapeutics

In other news, CEO Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock in a transaction on Monday, August 12th. The stock was sold at an average price of $11.53, for a total transaction of $57,650.00. Following the transaction, the chief executive officer now owns 120,695 shares in the company, valued at approximately $1,391,613.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 15,000 shares of company stock valued at $151,400 in the last three months. 4.50% of the stock is currently owned by company insiders.

Institutional Trading of Lexeo Therapeutics

Several institutional investors have recently made changes to their positions in LXEO. Janus Henderson Group PLC boosted its position in Lexeo Therapeutics by 9.0% during the first quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company's stock valued at $39,802,000 after purchasing an additional 210,047 shares during the last quarter. Artal Group S.A. lifted its holdings in shares of Lexeo Therapeutics by 32.9% during the 1st quarter. Artal Group S.A. now owns 801,716 shares of the company's stock valued at $12,571,000 after buying an additional 198,281 shares during the last quarter. RA Capital Management L.P. bought a new stake in shares of Lexeo Therapeutics in the 1st quarter valued at approximately $10,364,000. Vanguard Group Inc. increased its holdings in Lexeo Therapeutics by 15.8% in the first quarter. Vanguard Group Inc. now owns 481,755 shares of the company's stock worth $7,554,000 after buying an additional 65,573 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Lexeo Therapeutics by 12.3% in the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company's stock worth $510,000 after buying an additional 3,483 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.